期刊文献+

苯磺酸左旋氨氯地平联合贝那普利治疗原发性高血压并左室肥厚的临床分析 被引量:7

The clinical analysis of levamlodipine besylate combined with benazepril in treatment of primary hypertension with left ventricular hypertrophy
原文传递
导出
摘要 目的观察苯磺酸左旋氨氯地平联合贝那普利治疗原发性高血压并左室肥厚的临床疗效。方法将98例原发性高血压并左室肥厚患者按随机数字表法分为两组,每组49例,观察组采用苯磺酸左旋氨氯地平联合贝那普利治疗,对照组仅采用苯磺酸左旋氨氯地平治疗,比较两组的临床疗效及收缩压、舒张压、左室后壁厚度(LVPW)、左室舒张末期室间隔厚度(IVST)、左室舒张末期内径(LVEDD)、左室质量指数(LVMI)的差异。结果观察组总有效率为93.9%(46/49),显著高于对照组的77.6%(38/49),差异有统计学意义(r=5.333,P〈0.05)。两组治疗前收缩压及舒张压水平比较差异无统计学意义(P〉0.05)。治疗后两组收缩压及舒张压均较治疗前显著下降(P〈0.05);并且观察组治疗后收缩压及舒张压水平显著低于同期对照组[(121.27±8.69)mmHg(1mmHg=0.133kPa)比(131.54±9.85)mmHg,(82.45±4.69)mmHg比(88.49±5.14)mmHg](P〈0.05)。两组治疗前LVPW、IVST、LVEDD及LVMI水平比较差异无统计学意义(P〉0.05),治疗后两组LVPW、IVST、LVEDD及LVMI均明显下降(P〈0.05),并且观察组治疗后LVPW、IVST、LVEDD及LVMI明显低于同期对照组[(9.42±1.58)mm比(11.41±1.92)mm,(9.56±1.31)mm比(11.38±1.85)mm,(47.86±2.38)mm比(51.46±3.25)mm,(108.16±6.24)g/m^2比(119.21±7.68)g/m^2](P〈0.05)。结论苯磺酸左旋氨氯地平联合贝那普利对原发性高血压并左室肥厚患者进行治疗,能够明显降低血压,改善患者左室肥厚状态,值得临床推广应用。 Objective To observe the effect of levamlodipine besylate combined with benazepril in treatment of primary hypertension with left ventricular hypertrophy. Methods Ninety-eight primary hypertension with left ventricular hypertrophy patients were divided into two groups by random number table. Observation group(49 cases) was treated with levamlodipine besylate combined with benazepril, and controlgroup (49 cases) was only treated with levamlodipine besylate. The clinical effect,the levels of systolic blood pressure (SBP), diastolic blood pressure (DBP),left ventricular posterior wall (LVPW),interventricular septal thickness (IVST), left ventricular end-diastolic dimension (LVEDD) and left ventricular mass index (LVMI) were compared between two groups. Results The total effective rate in observation group was 93.9%(46/49), which was significantly higher than that in control group (77.6%, 38/49)( x^2 = 5.333,P 〈0.05 ). Before treatment,the differences were not statistically significant in the levels of SBP and DBP (P 〉 0,05). After treatment, the levels of SBP, DBP,LVPW, IVST, LVEDD and LVMI were significantly decreased in both groups (P 〈 0.05). Moreover, the levels of SBP, DBP, LVPW, IVST, LVEDD and LVMIin observation group after treatment were significantly lower than those in control group[ ( 121.27± 8.69 ) mmHg( 1 mm Hg = 0.133 kPa) vs. ( 131.54 ±9.85 ) mm Hg, (82.45 ± 4.69) mm Hg vs. (88.49 ± 5.14) mmHg, (9142 ± 1.58 ) mm :vs.( 11.41 ± 1.92) mm, (9.56 ± 1.31 ) mm vs.( 11.38 ± 1.85 ) mm, (47.86 ± 2.38 ) mm vs. (51.46±3.25) ram, (108.16 ±6.24) g/m^2 vs. (119.21 ±7.68) g/m^2] (P 〈0.05). Conclusion Levamlodipine besylate combined with benazepril in treatment of primary hypertension with left ventricular hypertrophy can improve the clinical effects and ease left ventricular hypertrophy status, which can be applied in clinic.
作者 陈正迪
出处 《中国医师进修杂志》 2012年第7期17-19,共3页 Chinese Journal of Postgraduates of Medicine
关键词 氨氯地平 高血压 心脏扩大 贝那普利 Amlodipine Hypertension Cardiomegaly Benazepril
  • 相关文献

参考文献9

二级参考文献37

共引文献39

同被引文献40

  • 1Stender S,Budinski D,Hounslow N.Pitavastatin demonstrates long-term efficacy,safety and tolerability in elderly patients with primary hypercholesterolaemia or combined (mixed)dyslipidaemia. Eur J Prev Cardiol . 2013
  • 2Carlsson AC,Wandell P,Sundquist K,et al.Differences and time trends in drug treatment of atrial fibrillation in men and women and doctors’’adherence to warfarin therapy recommendations:a Swedish study of prescribed drugs in primary care in2002and2007. European Journal of Clinical Pharmacology . 2013
  • 3White D,Kassim A,Bhaskar B,et al.Results from AMBER,a randomized phase2study of bevacizumab and bortezomib versus bortezomib in relapsed or refractory multiple myeloma. Cancer . 2013
  • 4Rosati G,Avallone A,Aprile G,et al.XELOX and bevacizumab followed by single-agent bevacizumab as maintenance therapy as first-line treatmentin elderly patients with advanced colorectal cancer:the boxe study. Cancer Chemother . 2013
  • 5Qi Jun. Amlodipine atorvnstatin calcium tablet treatment for hypertension combined clinical value of coronary heart disease[J].Journal of Hebei Medicine,2012,(6):755-757.
  • 6European Society of Hyertension European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension European Society of Cardiology Guidelines for the management of arterial hypertension[J].{H}Hypertension,2003,(6):1011-1012.
  • 7李琼华.氨氯地平联合美托洛尔治疗原发性高血压100例临床效果观察[J].医药前沿,2013, 7(1): 177- 178.
  • 8宋兴富.美托洛尔联合依那普利治疗原发性高血压疗效分析[J].医药前沿,2013’ 1(3):206- 107.
  • 9Liu ZJ,Zheng XL,Yang XR,et al.Affinity and specificity of levamlodipine-human serum albumin interactions:Insights into its carrier function.Biophys J,2012,10:3917-3925.
  • 10Zannad F,Matzinger A,Larche J.Trough/peak rations of once-daily angiotensin converting enzyme inhibitors and calcium antagonists.Am J Hypertens,2012,12:633-643.

二级引证文献29

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部